UnitedHealthcare implanted spinal drug delivery Coverage Update

Coverage Criteria for Implanted Spinal Drug Delivery Systems

Chronic Non-Malignant Pain — Initial and Implantation Criteria

Covered when ALL of the following are met

Chronic non-malignant pain initial criteria

Age > 18 years>18 years
chunk 6
Etiology of pain is known and clearly documented
chunk 6
Further treatment or surgical intervention for underlying condition is not indicated or refused
chunk 6
Conservative treatment failure: Documentation of treatment failure due to intolerable side-effects or failure to provide analgesia safely after a minimum of a 6-month trial of conservative methods (e.g., pharmacologic, physical therapy, behavioral health)>=6 months
chunk 9
Psychosocial assessment: Documentation of the absence of underlying, untreated psychological or psychosocial issues that will interfere with successful pain treatment
chunk 9
Successful trial prior to implantation: Completion of a drug infusion trial meeting above criteria with documentation of >50% reduction in pain during trial>50%
chunk 9

ref

title

ref_extra_removed_for_schema_compliance

ref_value_error_fixing

Replacement of Device

Replacement covered when ALL of the following are met

Replacement of device: Individual met all criteria for initial placement and the existing device is non-functional and cannot be repaired or is no longer under warranty

chunk 10

Cancer-Related Pain and Spasticity

Coverage for these indications follows referenced criteria

Cancer-related pain: Epidural or intrathecal drug infusion trial or catheter pump placement for cancer-related pain is proven and medically necessary in certain circumstances; refer to InterQual CP: Procedures, Epidural or Intrathecal Catheter Placement for specific clinical criteria

chunk 4

Spasticity: Epidural or intrathecal drug infusion trial or catheter pump placement for severe spasticity is proven and medically necessary in certain circumstances; refer to InterQual CP: Procedures, Epidural or Intrathecal Catheter Placement for specific clinical criteria

chunk 5

Replacement device and evidence context

Covered when ALL of the following are met (as updated in this policy):

Replacement device coverage: Replacement of the device is medically necessary when the individual has met all criteria for initial placement and the existing device is non-functional and either cannot be repaired or is no longer under warranty.

From Policy History/Revision Information.

Evidence support: Systematic reviews, meta-analyses, and multiple observational studies suggest IDDS can reduce pain intensity and improve some quality-of-life measures for cancer-related pain; evidence for noncancer pain is largely observational with limited RCTs and further RCTs are needed.

Synthesizes chunk 23 and policy history in chunk 35

This policy does not address individuals younger than 18 years of age. The coverage criteria and replacement provisions described in this document apply only to adult members (age ≥18 years).

FDA approval information in this policy is provided for reference only. FDA approval alone is not a basis for coverage; specific devices may require individual review. The FDA product code LKK identifies implanted programmable infusion pumps (class III devices) and the Premarket Approval database can be searched for manufacturer, device name, or PMA number for device-specific details.

Replacement of an implanted device is not indicated when the existing device is functional, repairable, or still under warranty. Replacement is considered medically necessary only when the member has met all initial placement criteria and the existing device is non-functional and either cannot be repaired or is no longer under warranty.

The body of evidence for implanted intrathecal drug delivery systems (IDDS) in chronic noncancer pain is mixed and generally limited. Professional society reviews cite predominantly observational studies with few RCTs; ASIPP characterized the evidence as 'limited' based on observational data, while ASPN concluded evidence for chronic noncancer low back pain is of moderate to limited quality and noted gaps requiring additional randomized trials. The policy interprets this limited/moderate evidence base by applying stricter coverage criteria (e.g., prior conservative management and demonstration of clinical benefit during trial) for noncancer indications.

Conservative Therapy and Screening Trial Requirements

Must have failed or been intolerant to conservative therapy for >=6 months prior to considering trial/implantation

Conservative therapy duration: Documentation of treatment failure due to intolerable side-effects or failure to provide analgesia safely after a minimum 6-month trial of conservative methods (pharmacologic, physical therapy, behavioral health)>=6 months

chunk 9

Screening trial demonstrating adequate response (often defined as ≥50% pain reduction) is expected prior to implantation.

Trial requirement: Completion of a screening epidural or intrathecal drug infusion trial demonstrating clinically significant pain reduction (commonly defined as ≥50% reduction from baseline) without adverse effects is required prior to permanent pump implantation; documentation of the percent pain reduction during trial must be included

Applicable Coding

Applicable CPT CodesCPT

62320	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance.
62321	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (i.e., fluoroscopy or CT).
62322	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
62323	Injection(s), of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (i.e., fluoroscopy or CT).
62324	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance.
62325	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (i.e., fluoroscopy or CT).
62326	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance.
62327	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (i.e., fluoroscopy or CT).
62350	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy.
62351	Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; with laminectomy.

1–10 of 13

1/2

inv-10: Pain reduction during trial — required threshold for non-malignant pain trial

Required trial pain reduction>50% reduction in pain during drug infusion trial

Minimum conservative therapy durationDocumentation of treatment failure after a minimum 6-month trial of conservative methods (pharmacologic, physical therapy, behavioral health)

Age requirementAge > 18 years (policy does not address individuals younger than 18)

Psychosocial assessmentDocumentation of absence of untreated psychological or psychosocial issues that would interfere with treatment

Completion of trialCompletion of an intrathecal or epidural drug infusion trial meeting the above documentation criteria prior to implantation

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for the listed CPT codes before services are rendered. Submit medical record documentation that supports medical necessity per policy criteria (see Required Medical Records). Failure to obtain prior authorization may result in claim denial or delayed payment.

Affected CPT codes: 62326, 62327, 62350, 62351, 62360, 62361, 62362
Authorization required for initial placement and replacement when performed (see coverage criteria)
Ensure prior authorization request includes documentation of completed drug infusion trial with >50% pain reduction for non-malignant pain

Denial Risk

Denial Risk — Common Triggers

Claims may be denied if required documentation demonstrating medical necessity is missing or incomplete. Common triggers for denial include lack of evidence of a qualifying drug infusion trial, insufficient conservative management documentation, or incomplete details about prior treatments and diagnostic testing.

Imaging and Procedural Guidance Requirements

Billing Rule

Perform injections/catheter placements with imaging guidance when CPT specifies

When CPT descriptors indicate 'with imaging guidance' (e.g., 62321, 62323, 62325, 62327), epidural or intrathecal injections and indwelling catheter placements are expected to be performed with imaging guidance.

Examples: 62321, 62323, 62325, 62327 specify imaging guidance (fluoroscopy or CT)

Documentation Required

Include recent applicable imaging studies for implantation/replacement review

For review of initial implantation or replacement requests, include all recent applicable imaging studies and diagnostic tests as part of the documentation.

Recent applicable imaging studies are required in the medical record for review

Replacement and Frequency Limits

inv-24: IDDS replacement — Replacement allowed when device non-functional and cannot be repaired or no longer under warranty; frequency limits otherwise not specified

Replacement indicationReplacement is medically necessary when the individual met all criteria for initial placement and the existing device is non-functional and cannot be repaired or is no longer under warranty

Frequency limitsNo additional frequency limits specified in this section when replacement criteria above are met

Documentation updateMedical records must include dates, duration and reason for discontinuation of prior treatments and all recent applicable imaging studies and diagnostic tests for review

Background on Implanted Drug Delivery Systems

Implanted intrathecal drug delivery systems (IDDS) consist of an intrathecal catheter connected to a subcutaneous infusion pump that delivers medication into the cerebrospinal fluid. Pumps may be constant-flow or programmable and are used to administer agents such as intrathecal opioids or other approved medications; placement is typically preceded by a trial infusion to assess response prior to permanent implantation.

Key Definitions

inv-20: Implanted drug delivery system (IDDS) — composed of catheter and pump for intrathecal administration

CompositionAn implanted drug delivery system (IDDS) consists of a catheter and a constant-flow or programmable pump that delivers medication into the intrathecal cerebrospinal fluid

UseUsed to treat pain or spasticity; implantation is preceded by an intrathecal or epidural trial infusion to assess response

Regulatory contextImplantable infusion pumps for intrathecal administration are regulated by FDA as class III devices under product code LKK (implanted programmable infusion pump)

inv-21: Implantable infusion pump (LKK) — FDA product code LKK description

FDA product code descriptionProduct code LKK: implanted programmable infusion pump (class III medical device)

Regulatory note

Non-Covered Items

No explicit procedural exclusions are listed in this portion of the policy. The document reiterates that FDA approval alone is informational and is not a guarantee of coverage; device-specific approvals are available through the FDA Premarket Approval database but do not by themselves establish medical necessity under this policy.